Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and a 2.60% dividend yield, against CRISPR Therapeutics, a gene-editing biotech pioneer with only $3.5M in revenue but groundbreaking CASGEVY therapy. While CRISPR offers high-growth potential, it remains unprofitable with significant losses. The author recommends Amgen for most investors seeking stability and predictable returns, though acknowledges CRISPR's improving commercial trajectory makes it a more compelling speculative opportunity than previously.

09/11/2026, 11:09 AM • The Motley Fool

Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons

Major stock indices declined on September 8, 2026, as rising crude oil prices approaching $100/barrel and geopolitical tensions weighed on markets. The Dow fell 1.18%, S&P 500 dropped 0.58%, and Nasdaq declined 0.31%. Notable movers included Intel gaining 9% on pricing plans, Corning rising 7% on a Verizon fiber deal, while Amgen and Novartis fell sharply following a drug trial setback. Qualcomm signed a major AI chip deal with Amazon worth up to $60 billion.

09/08/2026, 5:16 PM • The Motley Fool

1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.

09/08/2026, 2:37 PM • The Motley Fool

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

09/07/2026, 6:52 AM • GlobeNewswire

Where Will SCHD Stock Be in 5 Years?

The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a 57% total return over three years and is recommended as a strong buy for income-focused investors seeking stability and diversification. While the fund offers solid dividend growth (7.53% annually) and exposure to mature, profitable companies, its limited tech exposure (8.2%) means it will miss out on AI-driven gains that boosted the Nasdaq-100 by 92%. The outlook remains positive for the next five years if the U.S. economy continues growing, though trade policy uncertainty and rising bond yields present near-term risks.

09/06/2026, 12:23 PM • The Motley Fool

Schwab U.S. Dividend Equity vs. Vanguard Dividend Appreciation: Which ETF Looks Better for Your Portfolio?

Schwab U.S. Dividend Equity ETF (SCHD) offers nearly double the dividend yield of Vanguard Dividend Appreciation ETF (VIG) at 3% versus 1.5%, with a value-focused portfolio in healthcare and consumer defensives. VIG emphasizes technology stocks and requires 10-year dividend growth streaks. SCHD showed stronger one-year returns (29.5% vs 17.1%) and lower volatility, making it the analyst's preferred choice for income investors seeking higher yields.

09/05/2026, 8:15 AM • The Motley Fool

Want $500 a Month in Passive Income? Start With This Brilliant Dividend ETF.

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as an effective vehicle for generating sustainable passive income through dividends. With a 3.2% yield and a history of increasing annual dividends since 2011, investors would need approximately $187,500 invested to generate $500 monthly in dividend income. The fund focuses on high-quality dividend-paying stocks and has delivered 13.4% annual returns since inception.

09/04/2026, 5:22 AM • The Motley Fool

If the AI Boom Slows Down, History Says This Is the Smartest Way to Protect Your Long-Term Portfolio

As concerns grow about a potential AI market slowdown due to inflation, rate hikes, and geopolitical tensions, investors should consider diversifying into dividend-focused ETFs like SCHD. The Schwab U.S. Dividend Equity ETF offers exposure to 100 stable, dividend-paying stocks across multiple sectors, providing a defensive hedge against AI stock volatility while delivering steady income and historical returns of 243% over the past decade.

09/02/2026, 2:05 PM • The Motley Fool

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ

Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.

09/02/2026, 12:12 PM • The Motley Fool

If You'd Invested $1,000 in SCHD 10 Years Ago, Here's How Much You'd Have Today

The Schwab U.S. Dividend Equity ETF (SCHD) has delivered approximately 13% annual returns over the past decade, turning a $1,000 investment into roughly $3,400 with reinvested dividends. The fund's stringent selection criteria focusing on balance sheet quality, yield, and dividend growth history have produced a durable, high-quality portfolio. The article emphasizes the importance of buy-and-hold investing through market downturns and consistent dividend reinvestment for long-term wealth creation.

08/31/2026, 9:30 AM • The Motley Fool

Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel

The global palmoplantar pustulosis market is experiencing steady growth driven by increased awareness, diagnosis rates, and development of targeted biologic therapies. Key advances in IL-23 and IL-36 research, precision medicine, and AI-assisted diagnostics are accelerating treatment development. While topical therapies remain central for mild cases, systemic agents and biologics are supporting moderate-to-severe disease management. Growth is reinforced by clinical trials and regulatory approvals across North America, Europe, and Asia-Pacific, though high treatment costs and limited access in developing regions remain challenges.

08/31/2026, 5:03 AM • GlobeNewswire

Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with a lower 0.35% expense ratio and concentrated biotech focus, versus Invesco Pharmaceuticals ETF (PJP) with higher dividend yield and broader pharma exposure. Despite PJP's superior 5-year performance and lower volatility, the article concludes BBH is the better buy based on recent outperformance, though both funds offer targeted healthcare sector exposure with different risk-return profiles.

08/28/2026, 11:31 AM • The Motley Fool

Breast Cancer Therapeutics Market Size to Reach USD 95.14 Billion at a CAGR of 9.20% from 2035 – SNS Insider

The global breast cancer therapeutics market is projected to grow from USD 39.46 billion in 2025 to USD 95.14 billion by 2035, with a CAGR of 9.20%. Growth is driven by increased adoption of targeted therapies, CDK4/6 inhibitors, immunotherapy, and antibody-drug conjugates. North America leads with 38.61% market share, while Asia Pacific shows the fastest growth. Targeted therapy dominates with 64.85% share, while immunotherapy is the fastest-growing segment at 14.25% CAGR.

08/28/2026, 9:00 AM • GlobeNewswire

AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

08/25/2026, 12:46 PM • GlobeNewswire

Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket?

Invesco Nasdaq Biotechnology ETF (IBBQ) emerges as the better choice over VanEck Biotech ETF (BBH) for most investors. IBBQ offers broader diversification with 251 holdings, lower fees (0.19% vs 0.35%), higher dividend yield (0.8% vs 0.4%), and superior 5-year returns ($1,338 vs $1,061 on $1,000 invested). While BBH's concentrated 25-stock portfolio provides focused exposure to biotech leaders, it carries higher single-company risk without compensating benefits.

08/22/2026, 7:05 AM • The Motley Fool